Method for the treatment of a relapsing-remitting condition
The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.
1. A method for the treatment of an acute respiratory distress syndrome (ARDS) associated with a respiratory infection, the method comprising the step of administering to a subject in need thereof an effective amount of a peptide molecule comprising an amino acid sequence as set forth in SEQ ID NO:1, or having more than 95% identity to the amino acid sequence as set forth in SEQ ID NO:1, wherein the acute treatment method causes remission of the ARDS in the subject.
2. The method of claim 1 , wherein the peptide molecule is less than 50 amino acid residues in length.
3. The method of claim 1 , wherein the peptide molecule is less than 40 amino acid residues in length.
4. The method of claim 1 , wherein the peptide molecule consists of the amino acid sequence of SEQ ID NO:1.
5. The method of claim 1 , wherein the remission comprises reduction, alleviation or elimination of one or more symptom of the ARDS.
6. The method of claim 5 , wherein the one or more symptom of the ARDS is selected from the group consisting of: low blood oxygen, labored and unusually rapid breathing, clicking, bubbling, or rattling sounds in the lungs when breathing, low blood pressure, and extreme tiredness.
7. The method of claim 1 , wherein the remission comprises reduction, alleviation or elimination of one or more symptoms of the ARDS for a period of time which significantly exceeds a plasma pharmacokinetic half-life of the peptide molecule.
8. The method of claim 1 , wherein the remission is maintained when a plasma concentration of the peptide molecule is below a lower limit of quantification.
9. The method of claim 1 , wherein the remission comprises a significant decrease in the amount of one or more inflammatory marker selected from a cytokine or a chemokine in the subject relative to a control subject.
10. The method of claim 9 , wherein the one or more inflammatory marker are selected from the group consisting of: TNF-α, IFN-γ, IL-1γ, IL-6, KC/IL-8, IL-10, IL-17, MCP-1, MIP-1α, MIP-3α, G-CSF, and GM-CSF.
11. The method of claim 1 , wherein the respiratory infection is caused by a pathogen selected from the group consisting of: a viral pathogen, a bacterial pathogen, a fungal pathogen, and parasitic pathogen.
12. The method of claim 11 , wherein the viral pathogen is selected from the group consisting of: Influenza A, H1N1, H5N1, H7N9, severe acute respiratory syndrome (SARS), severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and Middle East Respiratory Syndrome (MERS).
13. The method of claim 11 , wherein the bacterial pathogen is selected from the group consisting of: Streptococcus pneumoniae, Staphylococcus aureus, Legionella pneumophila, Pneumocystis jirovecii , and an enteric gram-negative organism.
14. The method of claim 1 , wherein the respiratory infection is a hospital-acquired pneumonia (HAP) caused by a pathogen selected from the group consisting of: Influenza A, Respiratory Syncytial Virus (RSV), human metapneumovirus (hMPV), and a human parainfluenza virus (HPIV) selected from HPIV-1, HPIV-2, HPIV-3, HPIV-4a and HPIV-4b.
15. The method of claim 1 , wherein the respiratory infection is caused by Influenza A.
16. The method of claim 1 , wherein the subject is further administered one or more additional therapeutic agents.
17. The method of claim 16 , wherein the one or more therapeutic agent is selected from the group consisting of: a disease modifying agent, an analgesic, an anti-inflammatory agent, an anti-allergic drug, an allergen immunotherapeutic agent, an antiviral, an antibiotic, an antibody, and a steroid.